Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $174,006.56 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 2,812 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $61.88, for a total value of $174,006.56. Following the transaction, the vice president owned 105,272 shares of the company’s stock, valued at $6,514,231.36. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Elliott Boulding also recently made the following trade(s):

  • On Friday, October 9th, Mark Boulding sold 192 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.26, for a total value of $12,337.92.
  • On Monday, October 5th, Mark Boulding sold 1,638 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.03, for a total transaction of $104,881.14.
  • On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60.

PTC Therapeutics Price Performance

Shares of PTCT traded down $0.13 during trading hours on Wednesday, hitting $60.23. The stock had a trading volume of 642,752 shares, compared to its average volume of 1,332,788. The company’s fifty day moving average is $63.78 and its two-hundred day moving average is $70.12. PTC Therapeutics, Inc. has a 52 week low of $58.80 and a 52 week high of $90.87. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -43.02, a P/E/G ratio of 4.47 and a beta of 0.52.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.76). The company had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. During the same period in the prior year, the company earned $0.20 earnings per share. The firm’s revenue was up 69.6% compared to the same quarter last year. Equities analysts predict that PTC Therapeutics, Inc. will post 0.49 EPS for the current fiscal year.

PTC Therapeutics announced that its Board of Directors has authorized a stock buyback program on Tuesday, November 3rd that permits the company to buy back $500 million in shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 9.8% of its shares through open market purchases. Share buyback programs are often a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP acquired a new stake in PTC Therapeutics in the 2nd quarter valued at about $67,000. Harbor Investment Advisory LLC bought a new position in shares of PTC Therapeutics in the second quarter worth about $81,000. EverSource Wealth Advisors LLC raised its stake in shares of PTC Therapeutics by 16.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 151 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of PTC Therapeutics in the second quarter worth about $112,000. Finally, Jacobi Capital Management LLC bought a new position in shares of PTC Therapeutics in the third quarter worth about $91,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PTCT shares. Royal Bank Of Canada raised their price objective on shares of PTC Therapeutics from $75.00 to $77.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Citigroup boosted their target price on PTC Therapeutics from $108.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Zacks Research lowered PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Finally, Leerink Partners began coverage on PTC Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $98.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $99.23.

Get Our Latest Report on PTC Therapeutics

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Featured Stories

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.